Summary
8AT Chart
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.24 per share a year ago.
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.30 per share a year ago.
Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy
HC Wainwright & Co. analyst Raghuram Selvaraju upgraded Aclaris Therapeutics Inc ACRS from Neutral to Buy and a price target of $20. The stock gained after the rerating.
Aclaris Therapeutics Inc. Dividends
Aclaris Therapeutics Inc. Earnings
| 6 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 6 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 6 Jun 2025 Date | | - Cons. EPS | - EPS |
| 25 Feb 2025 Date | | - Cons. EPS | - EPS |
| 4 Nov 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 6 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 6 Jun 2025 Date | | - Cons. EPS | - EPS |
| 25 Feb 2025 Date | | - Cons. EPS | - EPS |
| 4 Nov 2024 Date | | - Cons. EPS | - EPS |
Aclaris Therapeutics Inc. (8AT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Aclaris Therapeutics Inc. ever had a stock split?
Aclaris Therapeutics Inc. Profile
| Medical - Diagnostics & Research Industry | Healthcare Sector | Neal S. Walker D.O., CEO | XBER Exchange | US00461U1051 ISIN |
| US Country | 61 Employees | - Last Dividend | - Last Split | 7 Oct 2015 IPO Date |
Overview
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel treatments for immune-inflammatory diseases. The company, founded in 2012 and based in Wayne, Pennsylvania, operates within the United States across two main segments: Therapeutics and Contract Research. The Therapeutics segment is focused on identifying and developing innovative therapies aimed at meeting the significant unmet needs in immuno-inflammatory diseases. Meanwhile, the Contract Research segment offers laboratory services, supporting the broader research and development efforts within the field.
Products and Services
- Zunsemetinib (ATI-450)
An MK2 inhibitor currently under Phase 1b/2 trials designed for the treatment of metastatic breast and pancreatic cancer. Zunsemetinib aims to address critical gaps in the treatment of these widespread and deadly cancers by targeting and inhibiting specific molecular pathways associated with tumor growth and spread.
- ATI-1777
A soft JAK 1/3 inhibitor that has completed Phase 2b trials for the treatment of moderate to severe atopic dermatitis, among other dermatologic conditions. ATI-1777 represents a novel approach in managing dermatologic conditions by modulating the immune response, potentially offering a therapeutic alternative for patients with limited treatment options.
- ATI-2138
An oral covalent inhibitor of ITK and JAK3, currently under Phase 1 trials as a potential treatment for T cell-mediated autoimmune diseases. ATI-2138 works by inhibiting specific enzymes involved in the activation of T cells, part of the immune system's response that can cause harmful inflammation in autoimmune diseases.
Contact Information
